Literature DB >> 7620118

Huntington's disease.

J F Gusella1, M E MacDonald.   

Abstract

Early in 1993, an unstable, expanded trinucleotide repeat in a novel gene of unknown function was identified on HD chromosomes. This discovery unleased a flurry of experimentation that has established the expanded CAG repeat the almost universal cause of the characteristic neurologic symptoms and pathology of this neurodegenerative disorder of midlife onset. The biochemical basis for the specific neuronal loss of HD remains uncertain, but the genetic lesion probably acts via its consequent polyglutamine segment in the protein product, huntingtin. This review will describe the basic parameters of the HD repeat's behavior and the knowledge that has accumulated concerning its potential mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620118     DOI: 10.1016/1043-4682(95)90011-x

Source DB:  PubMed          Journal:  Semin Cell Biol        ISSN: 1043-4682


  18 in total

1.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.

Authors:  J M Lecerf; T L Shirley; Q Zhu; A Kazantsev; P Amersdorfer; D E Housman; A Messer; J S Huston
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

2.  Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice.

Authors:  J A Bibb; Z Yan; P Svenningsson; G L Snyder; V A Pieribone; A Horiuchi; A C Nairn; A Messer; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 4.  The genetic defect causing Huntington's disease: repeated in other contexts?

Authors:  J F Gusella; F Persichetti; M E MacDonald
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

5.  Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.

Authors:  Emily Mitchell Sontag; Gregor P Lotz; Namita Agrawal; Andrew Tran; Rebecca Aron; Guocheng Yang; Mihaela Necula; Alice Lau; Steven Finkbeiner; Charles Glabe; J Lawrence Marsh; Paul J Muchowski; Leslie M Thompson
Journal:  J Neurosci       Date:  2012-08-08       Impact factor: 6.167

6.  Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease.

Authors:  Chi-Tso Chiu; Guangping Liu; Peter Leeds; De-Maw Chuang
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

7.  Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum.

Authors:  R J Ferrante; C A Gutekunst; F Persichetti; S M McNeil; N W Kowall; J F Gusella; M E MacDonald; M F Beal; S M Hersch
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

Review 8.  Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.

Authors:  Vittoria Pagliarini; Piergiorgio La Rosa; Claudio Sette
Journal:  Hum Genet       Date:  2017-04-22       Impact factor: 4.132

9.  Inactivation of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of a Huntington's disease model.

Authors:  Sheng Zhang; Mel B Feany; Sudipta Saraswati; J Troy Littleton; Norbert Perrimon
Journal:  Dis Model Mech       Date:  2009-04-06       Impact factor: 5.758

10.  Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes.

Authors:  Emily M Sontag; Lukasz A Joachimiak; Zhiqun Tan; Anthony Tomlinson; David E Housman; Charles G Glabe; Steven G Potkin; Judith Frydman; Leslie M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.